openPR Logo
Press release

OTC Cough, Cold and Allergy Medicine Market is Expected to Accelerate at a Whopping 5.5% CAGR by 2032

11-11-2022 08:24 AM CET | Health & Medicine

Press release from: Fact.MR

/ PR Agency: Fact.MR
According to Fact MR's recent market research, sales of OTC Cough, Cold, and Allergy Medicine to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, OTC Cough, Cold, and Allergy Medicine market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To remain 'ahead' of your competitors, request for a sample -
https://www.factmr.com/connectus/sample?flag=S&rep_id=71

To offer an in-depth overview, the report provides sales projections for over 20 countries. It also identifies segments exhibiting maximum growth.

Key Takeaways from Market Study

• Global OTC cough, cold, and allergy medicine market to top US$ 60 Bn by 2031.
• Bronchodialators projected to reach valuation of around US$ 25 Bn by 2031.
• Antihistamine projected to record above 4% CAGR over next 10 years.
• Market in APEJ holds share of more than 40%.
• Market in South Korea expected to reach valuation of US$ 15 Bn by 2031.
• Market in Australia to record 3% CAGR over forecast period of 2021- 2031.

"Increasing investments by public and government bodies in the healthcare sector, higher availability of a wide range of products, and easy access to self-administered drugs for minor allergies and illnesses are positively impacting sales of OTC cough, cold, and allergy medicines," says a Fact.MR analyst.

Key players in OTC cough, cold, and allergy medicine market

• Sanofi-Aventis
• Johnson & Johnson Service Inc.
• Reckitt Benckiser Group Plc.
• Novartis AG
• GlaxoSmithKline Plc.
• AstraZeneca Plc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Prestige Brands Holdings Inc.
• Procter & Gamble Co.
• Bristol-Myers Squib Co.
• Merck & Co.
• Allergen

Connect to an Expert-
https://www.factmr.com/connectus/sample?flag=AE&rep_id=71

Competitive Landscape

The market is hugely competitive with a number of top OTC cough, cold, and allergy medicine manufacturers. Few major players currently dominate the market in terms of revenue share.
Personalized patient care and access to complete end-to-end medical device products and services are now available from healthcare service providers and top companies in the OTC cough, cold & allergy medicine market.

Report Benefits & Key Questions Answered

• OTC Cough, Cold, and Allergy Medicine Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
• OTC Cough, Cold, and Allergy Medicine Historical volume analysis: The report provides a comparison of OTC Cough, Cold, and Allergy Medicine's historical sales and projected sales performance for 2021-2031.
• OTC Cough, Cold, and Allergy Medicine Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the OTC Cough, Cold, and Allergy Medicine market. It carefully gauges the impact of changing healthcare needs of key demographics globally
• OTC Cough, Cold, and Allergy Medicine Consumption by demographics: The report investigates consumer behavior affecting OTC Cough, Cold, and Allergy Medicine demand outlook for the assessment period. Effect of their keenness for digital trends on OTC Cough, Cold, and Allergy Medicine market is carefully analyzed
• Post COVID consumer spending on OTC Cough, Cold, and Allergy Medicine: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting OTC Cough, Cold, and Allergy Medicine market growth.

Get Full Access of this Report through our PayPal Payment Gateway
https://www.factmr.com/checkout/71

Key Segments Covered in the OTC Cough, Cold and Allergy Medicine Industry Survey

• By Drug Type :
o OTC Antihistamine
o OTC Expectorants
o OTC Bronchodilators
o OTC Antibiotics

• By OTC Channel :
o Pharmacies
o Drug Store
o Modern Trade
o Online

• By Dosage :
o Capsules
o Liquid
o Tablets
o Lozenges
o Others
 OTC Liquid Cough, Cold & Allergy Solutions
 OTC Liquid Cough, Cold & Allergy Drops
 OTC Liquid Cough, Cold & Allergy Granules
 OTC Liquid Cough, Cold & Allergy Syrup
 OTC Liquid Cough, Cold & Allergy Pills

• By Application :
o Babies
o Adults
o School-age Children

• By Region :
o North America
o Latin America
o Europe
o East Asia
o South Asia
o Oceania
o Middle East Africa

For more insights:

Dental Laboratories Market: https://www.newswire.co.kr/newsRead.php?no=947698

Bleeding Disorders Treatment Market: https://www.newswire.co.kr/newsRead.php?no=948105

21st floor , 136 Sejong-daero,
Seoul,100-768
South Korea

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OTC Cough, Cold and Allergy Medicine Market is Expected to Accelerate at a Whopping 5.5% CAGR by 2032 here

News-ID: 2803082 • Views:

More Releases from Fact.MR

Piston Ring Compressors Market Set to Reach USD 1.02 Billion by 2035: India Leads Growth with 7.8% CAGR, Innovation Driving Next-Gen Engine Assembly Efficiency
10-08-2025 | Health & Medicine
Fact.MR
Piston Ring Compressors Market Set to Reach USD 1.02 Billion by 2035: India Lead …
According to a recent study by Fact.MR, the global piston ring compressors market is poised to grow significantly from USD 615 million in 2025 to USD 1,021 million by 2035, expanding at a CAGR of 5.2%. This steady upward trend is being driven by the increasing demand for engine efficiency, precision assembly tools, and the global expansion of automotive and industrial machinery sectors. The manual piston ring compressors segment continues to
Non-Contact ECG Sensors Market to Surpass USD 4.1 Billion by 2035, Driven by AI-Powered Remote Cardiac Monitoring and Telehealth Expansion
10-08-2025 | Health & Medicine
Fact.MR
Non-Contact ECG Sensors Market to Surpass USD 4.1 Billion by 2035, Driven by AI- …
Fact.MR's latest study reveals a 12.2% CAGR for the Non-Contact ECG Sensors Market (2025-2035), signaling an era of intelligent, patient-friendly cardiovascular monitoring solutions. The global non-contact ECG sensors market is set to witness robust growth, rising from USD 1.3 billion in 2025 to USD 4.1 billion by 2035, according to a new report by Fact.MR. The market's trajectory reflects the growing preference for non-invasive, AI-integrated cardiac monitoring solutions, coupled with the
Bioelectric Catheters Market Poised to Surpass USD 9.7 Billion by 2035 Amid Growing Demand for AI-Driven and Minimally Invasive Cardiac & Neurological Interventions
10-08-2025 | Health & Medicine
Fact.MR
Bioelectric Catheters Market Poised to Surpass USD 9.7 Billion by 2035 Amid Grow …
The global Bioelectric Catheters Market is set to expand at an impressive CAGR of 10.4% between 2025 and 2035, rising from an estimated USD 3.6 billion in 2025 to reach USD 9.7 billion by 2035, according to the latest insights from Fact.MR. The market's rapid acceleration is attributed to the rising prevalence of cardiovascular and neurological diseases, increasing adoption of minimally invasive surgeries, and the integration of AI and IoT-enabled
AI-Based Spirometers Market Set to Surge to USD 536.9 Million by 2035 - Driven by AI Integration, Telehealth Expansion, and Preventive Respiratory Care
10-08-2025 | Health & Medicine
Fact.MR
AI-Based Spirometers Market Set to Surge to USD 536.9 Million by 2035 - Driven b …
The global AI-based spirometers market is on a strong growth trajectory, forecasted to climb from USD 89.7 million in 2025 to an impressive USD 536.9 million by 2035, according to a new study by Fact.MR. This growth, at a CAGR of 19.6%, underscores the transformative role of artificial intelligence (AI) in redefining respiratory diagnostics and patient monitoring worldwide. As healthcare systems globally shift toward preventive and precision medicine, AI-based spirometry devices

All 5 Releases


More Releases for OTC

Lawsuit filed for Investors who lost money with shares of adidas AG (OTC: ADDYY, …
An investor, who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), filed a lawsuit over alleged violations of Federal Securities Laws by adidas AG in connection with certain allegedly false and misleading statements. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. adidas AG (OTC: ADDYY, OTC: ADDDF) investors should contact
Investigation for Investors in adidas AG (OTC: ADDYY, OTC: ADDDF) announced over …
An investigation on behalf of investors in shares of adidas AG (OTC: ADDYY, OTC: ADDDF) was announced over potential breaches of fiduciary duties by certain officers and directors at adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain adidas AG officers and
AMERICAN HEMP VENTURES INC (OTC: AMHV) TO BECOME YOUNEEQAI TECHNICAL SERVICES In …
FOR IMMEDIATE RELEASE Denver Colorado, March 31, 2023, American Hemp Ventures, Inc. (OTC: AMHV) announced today that its name has changed effective immediately to YouneeqAI Technical Services inc. (OTC: YQAI) reflecting the Company's new focus into cookie-less AI technology services. The current management team has over 50 years of experience in technology services and innovation. Murray Galbraith, YQAI's CEO, is the Founder of YouneeqAI's software solution and has operated several private technology
Investigation announced for Investors who lost money with shares of adidas AG (O …
An investigation was announced for investors of adidas AG (OTC: ADDYY, OTC: ADDDF) shares over potential securities laws violations by adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of adidas AG (OTC: ADDYY,
Fuel Cell Market Technological Trends and Business Opportunities 2021 To 2026; P …
MarketInsightsReports has published a report titled global Fuel Cell Market research report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances, and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and prospective scenario of this market. The
Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to